Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
ConditionMoyamoya Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorBeijing Tiantan Hospital
About this trial
The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
The imaging examination meets the diagnostic criteria for moyamoya disease;
Sign the informed consent form;
Age ≥18 years old;
Baseline mRS score ≤2 points;
Disqualifiers
Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome;
Individuals under the age of 18;
Participants who refuse to take part in this study;
Pregnant patients;
Trial population
Patients diagnosed with MMD in Beijing Tiantan Hospital will be recruited. Eligibility will be determined through a checklist of inclusion and exclusion criteria.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Revascularization/Conservative management
DrugRevascularization/Conservative management
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Rate of participants experiencing cerebrovascular events (TIA, ischemic stroke, or hemorrhagic stroke)
The occurrence of cerebrovascular events, including TIA, ischemic stroke, or hemorrhagic stroke, will be assessed over an 18-month follow-up period.
Time frame
18 months during follow-upSecondary outcomes
1
Changes in Neurological Function (mRS, NIHSS) at 12 and 18 Months After Treatment
The mRS and NIHSS will be used to assess changes in neurological function at 12 and 18 months after treatment.
Time frame
12 and 18 months during follow-up2
Changes in Cognitive Function (MoCA, MMSE) at 12 and 18 Months After Treatment
The MoCA and MMSE will be used to evaluate changes in cognitive function at 12 and 18 months after treatment.
Time frame
12 and 18 months during follow-up3
Structural Remodeling of the Internal Carotid Artery Terminal and Middle Cerebral Artery Wall at 12 and 18 Months After Treatment
High-resolution magnetic resonance vessel wall imaging will be used to evaluate structural remodeling changes in the internal carotid artery terminal and middle cerebral artery wall at 12 and 18 months after treatment.
Time frame
12 and 18 months during follow-up4
Changes in Cerebral Blood Perfusion at 12 and 18 Months After Treatment
ASL will be used to assess cerebral blood perfusion changes at 12 and 18 months after treatment.
Time frame
12 and 18 months during follow-upSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov